Biologics Spine Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure byJosh SandbergJune 13, 2019
Extremities Hospitals TissueGene, Inc. Announces Special Protocol Assessment (SPA) Agreement with the Food and Drug Administration (FDA) for its Phase 3 Clinical Trial of Invossa™ for Patients Suffering from Osteoarthritis of the Knee byJosh SandbergMay 19, 2015
Recon TissueGene, Inc. Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee byJosh SandbergMay 12, 2015
